PXS-5505A is under clinical development by Pharmaxis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs for Myelofibrosis have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PXS-5505A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PXS-5505A is under development for the treatment of myelofibrosis, kidney fibrosis, liver fibrosis, metastatic hepatocellular carcinoma, myelodysplastic syndrome, lung fibrosis, liver cancer, cholangiocarcinoma (CCA) pancreatic cancer, primary myelofibrosis, postpolycythemia vera (PV) myelofibrosis and post-essential thrombocythemia (ET) myelofibrosis. It is administered by oral route in the form of capsule. The drug candidate acts by targeting lysyl oxidase (LOX), LOX1, LOX2, LOX3 and LOX4 and is developed based on amine oxidase platform technology. It was also under development for melanoma, malignant mesothelioma, glioblastoma multiforme (GBM) and head and neck cancer.
Pharmaxis is a pharmaceutical research company that develops and commercialize healthcare products. The company provides products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lung function and relieves the mucus burden in the lungs of patients. It offers products pipeline such as orbital dry powder inhaler, PXS-4728A, LOXL-2 and ASM8. Pharmaxis provides solutions for cystic fibrosis, bronchiectasis, asthma and chronic obstructive pulmonary disease and inflammatory and fibrotic diseases such as nonalcoholic steatohepatitis and pulmonary fibrosis, among others. The company operates in Australia. Pharmaxis is headquartered in Sydney, New South Wales, Australia.
For a complete picture of PXS-5505A’s drug-specific PTSR and LoA scores, buy the report here.